This advertisement has not loaded yet, but your article continues below.
Author of the article:
Article content
BEIJING — China’s medical products regulator said on Wednesday it has approved the use of BRII Biosciences’ neutrialising antibody cocktail for COVID-19, the first treatment of its type against the disease approved in the country.
The medicine, a combination of BRII-196/BRII-198, was approved to treat mild COVID-19 and the disease of “normal type” with high risk of progressing to hospitalization or death in adults and teenagers aged 12-17, the National Medical Products Administration said in a statement. (Reporting by Roxanne Liu and Ryan Woo; Editing by Jan Harvey)
This advertisement has not loaded yet, but your article continues below.
Article content
Financial Post Top Stories
Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.
By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300